CANADA LIFE ASSURANCE Co boosted its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 17.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,175 shares of the biotechnology company's stock after purchasing an additional 6,200 shares during the quarter. CANADA LIFE ASSURANCE Co owned 0.07% of Repligen worth $5,924,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Signaturefd LLC increased its stake in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares during the period. Sava Infond d.o.o. bought a new position in shares of Repligen during the 4th quarter worth approximately $29,000. UMB Bank n.a. boosted its stake in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after buying an additional 110 shares in the last quarter. Global Retirement Partners LLC grew its position in Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 129 shares during the period. Finally, Pilgrim Partners Asia Pte Ltd bought a new stake in Repligen in the fourth quarter valued at $55,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Repligen Stock Performance
Shares of NASDAQ:RGEN opened at $141.53 on Thursday. The stock has a market capitalization of $7.95 billion, a P/E ratio of -277.50, a P/E/G ratio of 4.54 and a beta of 1.27. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52. The business has a 50-day moving average price of $139.84 and a two-hundred day moving average price of $145.67.
Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Equities analysts predict that Repligen Co. will post 1.72 earnings per share for the current year.
Insiders Place Their Bets
In other Repligen news, Director Margaret Pax bought 250 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.20% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on RGEN shares. JPMorgan Chase & Co. upped their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. StockNews.com cut shares of Repligen from a "hold" rating to a "sell" rating in a research note on Thursday, April 17th. HC Wainwright reissued a "buy" rating and issued a $180.00 target price on shares of Repligen in a report on Friday, February 21st. TD Cowen started coverage on Repligen in a report on Monday, February 10th. They set a "buy" rating and a $200.00 price target for the company. Finally, Evercore ISI began coverage on Repligen in a research note on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective on the stock. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Repligen presently has an average rating of "Hold" and a consensus price target of $176.82.
Read Our Latest Report on Repligen
Repligen Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Recommended Stories
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
